Mary Reumuth Net Worth

The estimated Net Worth of Mary Reumuth is at least $440 ezer dollars as of 26 June 2024. Ms. Reumuth owns over 4,163 units of Kala Bio stock worth over $362,326 and over the last 7 years she sold KALA stock worth over $77,724. In addition, she makes $0 as Chief Financial Officer és Treasurer at Kala Bio.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Reumuth KALA stock SEC Form 4 insiders trading

Mary has made over 10 trades of the Kala Bio stock since 2020, according to the Form 4 filled with the SEC. Most recently she sold 4,163 units of KALA stock worth $19,774 on 26 June 2024.

The largest trade she's ever made was exercising 43,477 units of Kala Bio stock on 9 June 2020 worth over $114,779. On average, Mary trades about 3,414 units every 74 days since 2017. As of 26 June 2024 she still owns at least 60,187 units of Kala Bio stock.

You can see the complete history of Ms. Reumuth stock trades at the bottom of the page.

Mary Reumuth biography

Mary Reumuth CPA serves as Chief Financial Officer, Treasurer of the Company. She has served as our Chief Financial Officer since July 2017, Senior Vice President, Finance from February 2017 to July 2017, our Vice President, Finance from December 2014 to February 2017, our Senior Director, Finance from February 2014 to December 2014, as our Corporate Controller from February 2014 to July 2017 and Treasurer since February 2014. Prior to joining us, Ms. Reumuth acted as an independent financial consultant from November 2012 to January 2014 and, prior to that, served as Corporate Controller for Enobia Pharma Corp., or Enobia, a global biopharmaceutical company acquired by Alexion Pharmaceuticals, Inc., from May 2011 to June 2012. Prior to Enobia, Ms. Reumuth served as Director of Finance at Verenium Corporation, or Verenium, a biotechnology company, from December 2007 to March 2011. From 2001 to 2007, Ms. Reumuth held a variety of finance and accounting positions at Genzyme Corporation, or Genzyme, (now a Sanofi Company), and ILEX Oncology, Inc., or ILEX (acquired by Genzyme). Prior to ILEX, Ms. Reumuth was an auditor at Ernst & Young LLP. Ms. Reumuth earned her Bachelor’s degree in Business Administration from Texas A&M University—Corpus Christi, and is a Certified Public Accountant.

How old is Mary Reumuth?

Mary Reumuth is 45, she's been the Chief Financial Officer és Treasurer of Kala Bio since 2017. There are 16 older and 2 younger executives at Kala Bio. The oldest executive at Kala Bio Inc. is Dr. Kim Brazzell Ph.D., 68, who is the Head of R&D and Chief Medical Officer.

What's Mary Reumuth's mailing address?

Mary's mailing address filed with the SEC is C/O KALA BIO, INC., 1167 MASSACHUSETTS AVENUE, ARLINGTON, MA, 02476.

Insiders trading at Kala Bio

Over the last 7 years, insiders at Kala Bio have traded over $2,579,128 worth of Kala Bio stock and bought 23,705,318 units worth $209,975,371 . The most active insiders traders include Capital Management, L.P.Ra ..., Capital Management, L.P.Ra ... és Rajeev M. Shah. On average, Kala Bio executives and independent directors trade stock every 31 days with the average trade being worth of $2,090,132. The most recent stock trade was executed by Todd Bazemore on 26 June 2024, trading 4,653 units of KALA stock currently worth $22,102.

What does Kala Bio do?

kala pharmaceuticals, inc. (kala) is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based mucus penetrating particles, or mpp, technology, with an initial focus on the treatment of eye diseases. for more information, please visit kala’s website at www.kalarx.com.

Complete history of Ms. Reumuth stock trades at Kala Bio

Kala Bio executives and stock owners

Kala Bio executives and other stock owners filed with the SEC include:

• Mark Iwicki,
  Chairman of the Board, President, Chief Executive Officer
• Todd Bazemore,
  Chief Operating Officer
• Eric Trachtenberg,
  Chief Compliance Officer, General Counsel, Secretary
• Kim Brazzell,
  Chief Medical Officer
• Mark T. Iwicki,
  Chairman & CEO
• Dr. Kim Brazzell Ph.D.,
  Head of R&D and Chief Medical Officer
• Hongming Chen,
  Chief Scientific Officer
• Todd Bazemore,
  Pres & COO
• Andrew Koven,
  Lead Independent Director
• Rajeev Shah,
  Independent Director
• Gregory Perry,
  Independent Director
• Robert Paull,
  Independent Director
• Howard Rosen,
  Independent Director
• Gregory Grunberg,
  Independent Director
• Hannah Deresiewicz,
  IR Contact Officer
• Mary Reumuth,
  Chief Financial Officer, Treasurer
• James Patnoe,
  Sr. VP of Market Access, Commercial Operations & Pricing
• Vincent Kosewski,
  Sr. VP of Manufacturing & Supply Chain Management
• Michele LaRussa,
  Sr. VP of Regulatory Affairs & Quality Assurance
• Kathleen McCann Kline,
  Sr. VP of Marketing
• Eric L. Trachtenberg,
  Gen. Counsel, Chief Compliance Officer & Corp. Sec.
• Jill S. Steier,
  Exec. Director of Investor Relations & Corp. Communications
• Mary Reumuth CPA, CPA,
  CFO & Treasurer
• Dr. Justin Hanes Ph.D.,
  Founder & Chair of the Scientific Advisory Board
• Capital Partners Ii, Llcenr...,
  
• Harbor Master Investors (Ca...,
  10% owner
• Associates, L.L.C.Caxton Co...,
  
• Paulina Hill,
  Director
• Advisors Llc Orbi Med Capit...,
  
• Capital Management, L.P.Ra ...,
  
• Robert I Tepper,
  Director
• Robert Langer,
  Director
• Advisors Llc Orbi Med Capit...,
  
• Michele La Russa,
  Sr. VP, Regulatory and Quality
• C. Daniel Myers,
  
• Marjan Farid,
  
• Capital Management, L.P.Ra ...,
  
• Romulus K Brazzell,
  SEE REMARKS
• Mark S. Blumenkranz,
  
• Darius Kharabi,
  CHIEF BUSINESS OFFICER